Compare SWBI & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | CAPR |
|---|---|---|
| Founded | 1852 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.8M | 584.9M |
| IPO Year | 2000 | 2011 |
| Metric | SWBI | CAPR |
|---|---|---|
| Price | $15.71 | $9.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $17.25 | ★ $27.25 |
| AVG Volume (30 Days) | 640.0K | ★ 3.6M |
| Earning Date | 12-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | ★ 36.67 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $523,845,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $2.24 | $85.77 |
| P/E Ratio | $258.83 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $8.14 | $2.96 |
| 52 Week High | $17.56 | $40.37 |
| Indicator | SWBI | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 57.01 |
| Support Level | $13.94 | $7.78 |
| Resistance Level | $15.55 | $10.42 |
| Average True Range (ATR) | 0.56 | 0.98 |
| MACD | 0.20 | 0.38 |
| Stochastic Oscillator | 78.69 | 69.42 |
Smith & Wesson Brands Inc is a U.S.-based company engaged in manufacturing and selling firearms. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The company sells its products under the Smith and Wesson and Gemtech brands, which are used for defense, law enforcement, hunting, and sporting purposes. Geographically, it sells products globally, with maximum income being generated by the U.S. market from its handgun products.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.